Market capitalization | HKD140.64b |
Enterprise Value | HKD115.88b |
P/E (TTM) P/E ratio | 29.63 |
EV/Sales (TTM) EV/Sales | 8.72 |
P/S ratio (TTM) P/S ratio | 10.58 |
P/B ratio (TTM) P/B ratio | 4.61 |
Dividend yield | 1.45% |
Last dividend (FY23) | HKD0.34 |
Revenue growth (TTM) Revenue growth | 19.29% |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
24 Analysts have issued a Hansoh Pharmaceutical Group Company forecast:
24 Analysts have issued a Hansoh Pharmaceutical Group Company forecast:
Dec '24 |
+/-
%
|
||
Revenue | 13,293 13,293 |
19%
19%
|
|
Gross Profit | 12,094 12,094 |
21%
21%
|
|
EBITDA | 4,719 4,719 |
39%
39%
|
EBIT (Operating Income) EBIT | 4,284 4,284 |
44%
44%
|
Net Profit | 4,739 4,739 |
31%
31%
|
In millions HKD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Hansoh Pharmaceutical Group Co., Ltd. is a holding company, which engages in the research and development, production, and sale of a series of pharmaceutical products. Its products include oncology, anti-infective, anti-diabetic, gastrointestinal, and cardiovascular drugs. The company was founded by Huijuan Zhong on December 2, 2015 and is headquartered in Lianyungang, China.
Head office | Cayman Islands |
CEO | Hui Zhong |
Employees | 8,989 |
Founded | 2015 |
Website | www.hspharm.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.